Quipt Home Medical Corp., a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is pleased to announce that it has recently acquired a business with operations in Illinois, reporting unaudited trailing 12-month annual revenues of approximately $2.5 million.
- $2.5 Million in Annualized Revenues, 25% Projected Adjusted EBITDA Margin Post Integration, and Adds Over 3,700 Active Patients
- Quipt Has Completed 6 Acquisitions for Over $16 Million in Revenue, Adding Over 30,000 Active Patients Since July
CINCINNATI, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is pleased to announce that it has recently acquired a business with operations in Illinois, reporting unaudited trailing 12-month annual revenues of approximately $2.5 million. Post integration, Quipt expects an Adjusted EBITDA (defined below) for the acquisition target of $0.6 million. As a reminder all figures stated are in USD.
AcquisitionDetails
The acquisition adds a strategic location servicing Central Illinois, a heavily weighted respiratory product mix, and over 3,700 active patients. Moreover, the acquisition provides Quipt important insurance contracts and decades of operating experience, with an over 40-year operating track record in the markets served. The business has a diverse payor mix and full suite of products with a focus on respiratory care, representing over 85% of the mix.
The acquisition further expands Quipt’s operations in Illinois after the Company entered the market in August of 2020 and provides Quipt a coverage sphere between the major markets of St. Louis, Missouri and Chicago, Illinois. With the recent acquisitions, the expansionary operating footprint aligns closely with regions that have a high prevalence of COPD, a key target patient group; this includes Arkansas, Mississippi, Missouri, and Illinois, which are among the highest prevalence U.S. States. According to the NIH, about 570,000 people in Illinois have COPD.
The management team in place at the acquisition target has historically focused on a robust service intensive model, centered around patient education and compliance which is highly compatible with Quipt’s operating premise. This acquisition provides immediate cross selling and patient growth opportunities and adds patients to Quipt’s existing subscription-based resupply program.
Under the terms of the definitive purchase agreement, Quipt acquired the DME operation of the business for approximately $1.7 million in cash, and the real estate for $0.5 million. It is expected that post integration the acquisition will increase Quipt’s annual revenues by approximately $2.5 million and Adjusted EBITDA by $0.6 million.
ManagementCommentary
“Our robust operating engine and proven ability to integrate acquired assets allows us to continue the strong pace of closing strategic acquisitions. Since July we have now completed 6 acquisitions with combined revenues of over $16 million. Combining these newly acquired entities provides us a pathway to scale into new states with each business having a proven track record in the markets they serve and diversified product mixes. In this short period of time, we have amassed infrastructure in 4 new states and further penetrated existing states such as Illinois,” said Greg Crawford, Chairman and CEO of Quipt. “Given the favorable regulatory environment, we have been able to accelerate our expansion efforts by economically acquiring smaller respiratory focused home medical providers throughout the United States that fit our stringent acquisition criteria. This newest transaction in Illinois is another example of our strategy to make tuck-in acquisitions to fill in attractive geographies, obtain important insurance contracts, add to our active patient base, and build out our referring physician network. Our current pipeline consists of companies reflective of all three tiers of our previously disclosed acquisition strategy and we are extremely optimistic we will maintain momentum in closing targets that fit the mold.”
“I also want to take this opportunity to reiterate how strongly the underlying business continues to perform amongst the challenges presented from the global pandemic and supply chain constraints. Demand for respiratory equipment continues to be robust, and we have not seen any signs of that slowing. We are extremely excited with the operating excellence we have been able to display to date and look forward to carrying the strong momentum into 2022.”
Chief Financial Officer, Hardik Mehta added, “We continue on our strategic mission of growing into a national provider of respiratory focused homecare in the United States, and this acquisition once again showcases how we can lather on our existing platform to convert low margin businesses into high margin businesses through operating efficiencies and cost savings synergies. The transaction is reflective of this model and adds $2.5 million in revenue with an expectation that post integration it will have a 25% Adjusted EBITDA margin, with a heavily respiratory weighted product mix, and provides us additional infrastructure in Illinois. We continue to invest in technology to improve our operating efficiencies, whether through the ongoing use of our data driven tools, revenue cycle management or through our automated subscription-based resupply program. These actions drive sustained value to the company and allows us to continue to increase our productivity. Moreover, we have a robust balance sheet with over $30 million in cash, and a $20 million undrawn credit facility allowing us to strategically work through our acquisition pipeline, which includes larger revenue opportunities that meet our criteria, and I am extremely confident in our pace staying strong through the remainder of 2021 and into 2022.”
ABOUTQUIPTHOMEMEDICALCORP.
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.
There can be no assurance that any of the potential acquisitions in the Company’s pipeline or in negotiations will be completed asproposed or at all and no definitive agreements have been executed. Completion of any transaction will be subject to applicabledirector, shareholder and regulatory approvals.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of theTSXVentureExchange) acceptsresponsibility forthe adequacyor accuracyof thisrelease.
Forward-LookingStatements
Certainstatementscontainedinthispressreleaseconstitute “forward-lookinginformation” assuchtermisdefinedinapplicableCanadiansecuritieslegislation.Thewords “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company,including: post integration financial results (revenue and Adjusted EBITDA) of the acquisition target; the Company’s acquisition approach; the Company adding patients to its existing subscription-based resupply program; the Company being extremely optimistic that it will maintain momentum in closing additional targets; the Company converting low margin businesses into high margin businesses through operating efficiencies and cost savings synergies; and the Company being extremely confident in its acquisition pace staying strong through the remainder of 2021 and into 2022; are intended to identify forward-lookinginformation. All statements other than statements of historical fact may be forward-looking information. Suchstatements reflect the Company’s current views and intentions with respect to future events, and current informationavailable to the Company, and are subject to certain risks, uncertainties and assumptions, including: the acquisition targetsachievingresultsatleastasgoodashistoricalperformances;andtheCompanysuccessfullyidentified, negotiating and completing additional acquisitions, including accretive acquisitions. Many factors could cause theactual results, performance or achievements that may be expressed or implied by such forward-looking informationto vary from those described herein should one or more of these risks or uncertainties materialize. Examples of suchrisk factors include, without limitation: credit; market (including equity, commodity, foreign exchange and interestrate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory;legal; environmental; capital adequacy; the general business and economic conditions in the regions in which theCompany operates; the ability of the Company to execute on key priorities, including the successful completion ofacquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficultyintegratingnewlyacquiredbusinesses;theabilitytoimplementbusinessstrategiesandpursuebusinessopportunities;low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company’s informationtechnology, internet, network access or other voice or data communications systems or services; the evolution ofvarious types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties tocomply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of,current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drugdiscoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highlyregulatedbusiness;theoveralldifficultlitigationenvironment,includingintheU.S.;increasedcompetition;changesin foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition forfunding; the availability of funds and resources to pursue operations; critical accounting estimates and changes toaccountingstandards,policies, andmethodsused bythe Company;the occurrence of natural andunnaturalcatastrophic events and claims resulting from such events; and risksrelated to COVID-19 including variousrecommendations, orders and measures of governmental authorities to try to limit the pandemic, including travelrestrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and socialdistancing,disruptionstomarkets,economicactivity,financing,supplychainsandsaleschannels,andadeteriorationof general economic conditions including a possible national or global recession; as well as those risk factorsdiscussed or referred to in the Company’s disclosure documents filed with United States Securities and ExchangeCommission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces ofCanada and available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or shouldassumptions underlying the forward-looking information prove incorrect, the actual results or events may differmaterially from the results or events predicted. Any such forward-looking information is expressly qualified in itsentirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy orcompleteness of such forward-looking information. The forward-looking information included in this press release ismade as of the date of this press release and the Company undertakes no obligation to publicly update or revise anyforward-lookinginformation, other thanas required by applicablelaw.
Non-GAAPMeasures
Thispressreleaserefersto“AdjustedEBITDA”whichisanon-GAAPandnon-IFRSfinancialmeasurethatdoesnothave a standardized meaning prescribed by GAAP or IFRS. The Company’s presentation of this financial measuremay not be comparable to similarly titled measures used by other companies. This financial measure is intended toprovide additional information to investors concerning the Company’s performance. Adjusted EBITDA is defined asEBITDA excluding stock-based compensation. Adjusted EBITDA is a Non-IFRS measure the Company uses as anindicator of financial health and excludes several items which may be useful in the consideration of the financialconditionoftheCompany,asapplicable,includinginterestexpense,incometaxes,depreciation,amortization,stock-basedcompensation,goodwillimpairmentandchangeinfairvalueofdebenturesandfinancialderivatives.
For further information please visit our website at www.Quipthomemedical.com, or contact:
Cole Stevens
VP of Corporate Development
859-300-6455
cole.stevens@myquipt.com
Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
investorinfo@myquipt.com
